Antiepileptics, pregnancy and the child

Drug and Therapeutics Bulletin

Volumn 43, Issue 2, 2005, Pages 13-16

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FOLIC ACID; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VITAMIN K GROUP;

BLEEDING DISORDER; BREAST FEEDING; CHILD; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG MEGADOSE; EPILEPSY; EYE MALFORMATION; FEMALE; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HIGH RISK PATIENT; HUMAN; HYPOSPADIAS; INTRAUTERINE GROWTH RETARDATION; KIDNEY MALFORMATION; LOW BIRTH WEIGHT; META ANALYSIS; NAIL HYPOPLASIA; NEURAL TUBE DEFECT; NEWBORN; NEWBORN DEATH; NEWBORN DISEASE; OBSTETRIC CARE; PLANNING; POSTNATAL CARE; PREGNANCY DISORDER; PRESCRIPTION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKELETON MALFORMATION; STILLBIRTH; UROGENITAL TRACT DISEASE; VITAMIN K DEFICIENCY;

EID: 13844309396     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2005.43213     Document Type: Review

References (62)

1. Fairgrieve SD et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000; 321: 674-5.
2. Epilepsy Guidelines Group. Primary care guidelines for the management of females with epilepsy. London: Royal Society of Medicine Press Ltd, 2004.
3. Epilepsy and pregnancy. DTB 1994; 32: 49-51.
4. Adab N et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 15-21.
5. Gaily E, Granström M-L. Minor anomalies in children of mothers with epilepsy. Neurology 1992; 42 (suppl 5): 128-31.
6. Pschirrer ER. Seizure disorders in pregnancy. Obstet Gynecol Clin North Am 2004; 31: 373-84.
7. Dansky LV et al. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987; 21: 176-82.
8. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-7.
9. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832-5.
10. Joint Formulary Committee. British National Formulary. Edition 48. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, September 2004.
11. National Institute for Clinical Excellence, 2004. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care [online]. Available: http://www.nice.org.uk/pdf/CG020NICEguideline.pdf [Accessed 13 January 2005].
12. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 2000; 55 (suppl 1): S21-31.
13. Richmond JR et al. Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 2004; 190: 371-9.
14. Robert E et al. Evaluation of drug therapy and teratogenic risk in a Rhône-Alpes district population of pregnant epileptic women. Eur Neurol 1986; 25: 436-43.
15. Fried S et al. Malformation rates in children of women with untreated epilepsy. A meta-analysis. Drug Saf 2004; 27: 197-202.
16. Wide K et al. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93: 174-6.
17. Tennis P et al. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43: 1161-7.
18. Matalon S et al. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002; 16: 9-17.
19. Samrén EB et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981-90.
20. Arpino C et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE). Epilepsia 2000; 41: 1436-43.
21. Vajda FJ et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003; 10: 543-9.
22. Samrén EB et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739-46.
23. Kaneko S et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33: 145-58.
24. Craig J et al. The UK epilepsy and pregnancy register: update of results 1996-2003. Epilepsia 2004; 45 (suppl 7): 229 [abstract 2.112].
25. Holmes LB et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-8.
26. Canger R et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40: 1231-6.
27. Holmes LB et al. The AED (antiepileptic drug) pregnancy registry. A 6-year experience. Arch Neurol 2004; 61: 673-8.
28. Meischenguiser R et al. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004; 5: 163-7.
29. Kaaja E et al. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575-9.
30. Yerby MS. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia 2003; 44 (suppl 3): 33-40.
31. Wilton LV, Shakir S. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia 2002; 43: 983-92.
32. Montouris G. Gabapentin exposure in human pregnancy: results from the gabapentin pregnancy registry. Epilepsy Behav 2003; 4: 310-7.
33. Topamax tablets and sprinkle. Summary of product characteristics, UK. Janssen-Cilag Limited, August 2004.
34. Keppra. Summary of product characteristics, Belgium. UCB S.A, July 2004.
35. Lyrica capsules. Summary of product characteristics, UK. Pfizer Limited, September 2004.
36. Gaily E et al. Minor anomalies in offspring of epileptic mothers. J Pediatr 1988; 112: 520-9.
37. Hvas CL et al. Birth weight in offspring of women with epilepsy. Epidemiol Rev 2000; 22: 275-82.
38. Wide K et al. Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. Epilepsia 2000; 41: 854-61.
39. Scottish Intercollegiate Guidelines Network, 2003. Diagnosis and management of epilepsy in adults. A national clinical guideline [online]. Available: http://www.sign.ac.uk/pdf/sign70.pdf [Accessed 13 January 2005].
40. Dean JC et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002; 39: 251-9.
41. Boon P et al. Belgian consensus on recommendations for standards of care for women with epilepsy before, during and after pregnancy. Acta Neurol Belg 2004; 104: 6-12.
42. Frisium tablets 10mg. Summary of product characteristics, UK. Aventis Pharma Ltd, January 2002.
43. Rivotril tablets. Summary of product characteristics, UK. Roche Products Limited, March 2002.
44. Trileptal 150, 300, 600. Summary of product characteristics, UK. Novartis Pharmaceuticals UK Limited, May 2002.
45. Zarontin syrup and capsules. Summary of product characteristics, UK. Pfizer Limited, June 2003.
46. Epanutin capsules 25, 50, 100 and 300mg. Summary of product characteristics, UK. Pfizer Limited, March 2004.
47. Gabitril 5mg, gabitril 10mg, gabithl 15mg. Summary of product characteristics, UK. Cephalon UK Limited, November 2003.
48. Sabril sachets 0.5g and tablets 500mg. Summary of product characteristics, UK. Aventis Pharma Limited, May 2004.
49. Nootropil tablets 800mg, 1200mg, solution 33%. Summary of product characteristics, UK. UCB Pharma Ltd, March 2000.
50. Neurontin. Summary of product characteristics, UK Wamer Lambert, January 2004.
51. Lamictal combined tablets. Summary of product characteristics, UK. The Wellcome Foundation Ltd, September 2003.
52. Diamox sodium parenteral 500mg/vial. Summary of product characteristics, UK. Cyanamid of Great Britain Limited, February 2004.
53. Adab N et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1575-83.
54. Gaily E et al. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990; 32: 403-14.
55. Gaily E et al. Intelligence of children of epileptic mothers. J Pediatr 1988; 113:677-84.
56. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996; 75: 517-20.
57. Scolnik D et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271: 767-70.
58. Gaily E et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62: 28-32.
59. When and how to stop antiepileptic drugs in adults. DTB 2003; 41: 41-3.
60. Epilim. Summary of product characteristics, UK. Sanofi-Synthelabo, March 2004.
61. Tegretol chewtabs 100mg, 200mg,Tegretol tablets 100mg, 200mg, 400mg. Summary of product characteristics, UK. Novartis Pharmaceuticals UK Limited, January 2003.
62. Mysoline tablets. Summary of product characteristics, UK. AstraZeneca UK Limited, November 2003.